A 83-01 sodium salt
(Synonyms: 3-(6-Methylpyridin-2-yl)-N-phenyl-4-(quinolin-4-yl)-1H-pyrazole-1-carbothioamide, sodium salt) 目录号 : GC35210
A TGF-β type I receptor inhibitor
Cas No.:2828431-89-4
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
A 83-01 is an inhibitor of TGF-β type I receptor kinase (ALK5), activin type IB receptor (ALK4), and nodal type I receptor (ALK7) (IC50s = 12, 45, and 7.5 nM, respectively).1 It blocks the phosphorylation of SMAD2/3 and inhibits TGF-β-induced epithelial-to-mesenchymal transition.1 It has little effect on bone morphogenic type I receptors, p38 mitogen-activated protein kinase, or ERK.1 A 83-01 has been used to reprogram fibroblasts into alternative lineages, including neural stem cells and cardiomyocytes.2,3
1.Tojo, M., Hamashima, Y., Hanyu, A., et al.The ALK-5 inhibitor A-83-01 inhibits Smad signaling and epithelial-to-mesenchymal transition by transforming growth factor-βCancer Sci.96(11)791-800(2005) 2.Cao, N., Huang, Y., Zheng, J., et al.Conversion of human fibroblasts into functional cardiomyocytes by small moleculesScience352(6290)1216-1220(2016) 3.Zhang, M., Lin, Y.H., Sun, Y.J., et al.Pharmacological reprogramming of fibroblasts into neural stem cells by signaling-directed transcriptional activationCell Stem Cell18(5)653-667(2016)
| Cas No. | 2828431-89-4 | SDF | |
| 别名 | 3-(6-Methylpyridin-2-yl)-N-phenyl-4-(quinolin-4-yl)-1H-pyrazole-1-carbothioamide, sodium salt | ||
| Canonical SMILES | S=C(N1N=C(C2=NC(C)=CC=C2)C(C3=CC=NC4=CC=CC=C34)=C1)NC5=CC=CC=C5.[Na+] | ||
| 分子式 | C25H19N5NaS | 分子量 | 443.5 |
| 溶解度 | DMSO: 100 mg/mL (224.97 mM); Water: < 0.1 mg/mL (insoluble) | 储存条件 | 4°C, protect from light *Product is unstable in the solution state, it is recommended that you use it now and use it immediately |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.2548 mL | 11.274 mL | 22.5479 mL |
| 5 mM | 0.451 mL | 2.2548 mL | 4.5096 mL |
| 10 mM | 0.2255 mL | 1.1274 mL | 2.2548 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。